Eloralintide for Adults With Obesity Who Still Carry Excess Weight on a Weekly Incretin
Tests eloralintide against placebo in adults with obesity already taking a weekly incretin.
Plain-language title generated from the registry record
Registry title: A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
Key facts
- Where
- Chūōku, Izumisano, Kawasaki, Kisarazu, Kure, Kyoto, Matsuyama, Osaka, Sapporo, Shimonoseki, and Wakayama, JapanSee the 11 sites
- Phase
- Phase 3
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with obesity or overweight who are already on a stable weekly incretin treatment. Some may also have type 2 diabetes.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Persistent obesity or overweight: BMI ≥30 kg/m2, or ≥27 kg/m2 with at least one obesity-related condition (high blood pressure, abnormal blood fats, sleep apnea, heart or blood vessel disease, or type 2 diabetes).
- Earlier treatment
- Must be on stable incretin therapy at screening. Must not have taken DPP-4 inhibitors, amylin analogs or insulin within 90 days before screening.
Main reasons for not taking part
- Prior or planned surgery for obesity (some procedures allowed if done more than 1 year before screening)
- Prior or planned endoscopic procedure or device-based obesity treatment (prior device allowed if removed more than 6 months before screening)
- Type 1 diabetes
- Heart attack, stroke, coronary artery revascularization, unstable angina or hospitalization for heart failure within 90 days before screening
- History of New York Heart Association Class IV congestive heart failure
Read by machine on 12 November 2026.
Where in Japan
- The Institute of Medical Science, Asahi Life FoundationChūōku, JapanContact: Yukiko Onishi (principal investigator)Taking people
- Rinku General Medical CenterIzumisano, JapanContact: Tomoko Otsuki (principal investigator)Taking people
- Kanto Rosai HospitalKawasaki, JapanContact: Yoshio Nagai (principal investigator)Taking people
- Kimitsu Chuo HospitalKisarazu, JapanContact: Ryoichi Ishibashi (principal investigator)Taking people
- Kure Medical CenterKure, JapanContact: Mitsunobu Kubota (principal investigator)Taking people
- Takeda General Hospital - KyotoKyoto, JapanContact: KIminori Hosoda (principal investigator)Taking people
- Mikannohana Clinic, Diabetes, Endocrinology and MetabolismMatsuyama, JapanContact: Tetsuji Niiya (principal investigator)Taking people
- Kansai Electric Power HospitalOsaka, JapanContact: Yoshiyuki Hamamoto (principal investigator)Taking people
- Manda Memorial HospitalSapporo, JapanContact: Masahiko Kato (principal investigator)Taking people
- Shimonoseki Medical CenterShimonoseki, JapanContact: Kaoru Noda (principal investigator)Taking people
- Japanese Red Cross Society - Wakayama Medical CenterWakayama, JapanContact: Shizuka Kaneko (principal investigator)Taking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Eli Lilly and Company
- Trial code
- NCT07392190EU 2025-523659-73-00
- Record updated
- 4 November 2026
- Original description
The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with placebo in participants with persistent obesity or overweight, with or without type 2 diabetes, and on stable incretin background therapy.Read full original descriptionShow less
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Once Weekly Eloralintide in Adult Participants With Persistent Obesity or Overweight Treated With a Weekly Incretin, With and Without Type 2 Diabetes
The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with placebo in participants with persistent obesity or overweight, with or without type 2 diabetes, and on stable incretin background therapy.
Participation in the study will last about 80 weeks.
Inclusion: Are on stable incretin therapy at screening; With persistent obesity or overweight defined as:; ≥30 kg/m2 OR; ≥27 kg/m2 with at least one existing obesity related complication at screening:; hypertension; dyslipidemia; obstructive sleep apnea; cardiovascular disease (for example, ischemic cardiovascular disease, New York Heart Association Functional Class I-III heart failure), or; type 2 diabetes; Have a stable body weight (<5% body weight change) at screening.
Exclusion: Have a prior or planned surgical treatment for obesity (liposuction, cryolipolysis, or abdominoplasty allowed if performed >1 year before screening); Have a prior or planned endoscopic procedure and/or device-based therapy for obesity (prior device-based therapy acceptable if device removal was more than 6 months prior to screening); Have taken any of the following antihyperglycemic medications within 90 days before screening:; dipeptidyl peptidase-4 (DPP-4) inhibitors; amylin analogs; insulin; Have had within 90 days prior to screening:; heart attack; stroke; coronary artery revascularization; unstable angina, or; hospitalization due to congestive heart failure; Have type 1 diabetes; Have a history or diagnosis of New York Heart Association Functional Classification Class IV congestive heart failure.